Literature DB >> 29480158

Utilization of a hybrid finite-element based registration method to quantify heterogeneous tumor response for adaptive treatment for lung cancer patients.

Hoda Sharifi1, Hong Zhang, Hassan Bagher-Ebadian, Wei Lu, Munther I Ajlouni, Jian-Yue Jin, Feng-Ming Spring Kong, Indrin J Chetty, Hualiang Zhong.   

Abstract

Tumor response to radiation treatment (RT) can be evaluated from changes in metabolic activity between two positron emission tomography (PET) images. Activity changes at individual voxels in pre-treatment PET images (PET1), however, cannot be derived until their associated PET-CT (CT1) images are appropriately registered to during-treatment PET-CT (CT2) images. This study aimed to investigate the feasibility of using deformable image registration (DIR) techniques to quantify radiation-induced metabolic changes on PET images. Five patients with non-small-cell lung cancer (NSCLC) treated with adaptive radiotherapy were considered. PET-CTs were acquired two weeks before RT and 18 fractions after the start of RT. DIR was performed from CT1 to CT2 using B-Spline and diffeomorphic Demons algorithms. The resultant displacements in the tumor region were then corrected using a hybrid finite element method (FEM). Bitmap masks generated from gross tumor volumes (GTVs) in PET1 were deformed using the four different displacement vector fields (DVFs). The conservation of total lesion glycolysis (TLG) in GTVs was used as a criterion to evaluate the quality of these registrations. The deformed masks were united to form a large mask which was then partitioned into multiple layers from center to border. The averages of SUV changes over all the layers were 1.0  ±  1.3, 1.0  ±  1.2, 0.8  ±  1.3, 1.1  ±  1.5 for the B-Spline, B-Spline  +  FEM, Demons and Demons  +  FEM algorithms, respectively. TLG changes before and after mapping using B-Spline, Demons, hybrid-B-Spline, and hybrid-Demons registrations were 20.2%, 28.3%, 8.7%, and 2.2% on average, respectively. Compared to image intensity-based DIR algorithms, the hybrid FEM modeling technique is better in preserving TLG and could be useful for evaluation of tumor response for patients with regressing tumors.

Entities:  

Mesh:

Year:  2018        PMID: 29480158      PMCID: PMC6242271          DOI: 10.1088/1361-6560/aab235

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  23 in total

1.  Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake.

Authors:  Daniela Trani; Ala Yaromina; Ludwig Dubois; Marlies Granzier; Sarah G J A Peeters; Rianne Biemans; Georgi Nalbantov; Natasja Lieuwes; Brigitte Reniers; Esther E G C Troost; Frank Verhaegen; Philippe Lambin
Journal:  Clin Cancer Res       Date:  2015-08-14       Impact factor: 12.531

2.  elastix: a toolbox for intensity-based medical image registration.

Authors:  Stefan Klein; Marius Staring; Keelin Murphy; Max A Viergever; Josien P W Pluim
Journal:  IEEE Trans Med Imaging       Date:  2009-11-17       Impact factor: 10.048

3.  Evaluation of adaptive treatment planning for patients with non-small cell lung cancer.

Authors:  Hualiang Zhong; Salim M Siddiqui; Benjamin Movsas; Indrin J Chetty
Journal:  Phys Med Biol       Date:  2017-01-10       Impact factor: 3.609

Review 4.  Adaptive radiotherapy for lung cancer.

Authors:  Jan-Jakob Sonke; José Belderbos
Journal:  Semin Radiat Oncol       Date:  2010-04       Impact factor: 5.934

5.  Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer.

Authors:  Wouter van Elmpt; Michel Ollers; Anne-Marie C Dingemans; Philippe Lambin; Dirk De Ruysscher
Journal:  J Nucl Med       Date:  2012-08-09       Impact factor: 10.057

6.  18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?

Authors:  Kenneth J Biehl; Feng-Ming Kong; Farrokh Dehdashti; Jian-Yue Jin; Sasa Mutic; Issam El Naqa; Barry A Siegel; Jeffrey D Bradley
Journal:  J Nucl Med       Date:  2006-11       Impact factor: 10.057

Review 7.  Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.

Authors:  Rodney J Hicks
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

8.  Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group.

Authors:  T Arai; T Kuroishi; Y Saito; Y Kurita; T Naruke; M Kaneko
Journal:  Jpn J Clin Oncol       Date:  1994-08       Impact factor: 3.019

9.  FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.

Authors:  Pierre Lovinfosse; Zsolt Levente Janvary; Philippe Coucke; Sébastien Jodogne; Claire Bernard; Mathieu Hatt; Dimitris Visvikis; Nicolas Jansen; Bernard Duysinx; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-30       Impact factor: 9.236

10.   ¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose.

Authors:  Mariangela Massaccesi; Maria Lucia Calcagni; Maria Grazia Spitilli; Fabrizio Cocciolillo; Francesca Pelligrò; Lorenzo Bonomo; Vincenzo Valentini; Alessandro Giordano
Journal:  Radiat Oncol       Date:  2012-07-10       Impact factor: 3.481

View more
  2 in total

1.  Four-dimensional computed tomography-based biomechanical measurements of pulmonary function and their correlation with clinical outcome for lung stereotactic body radiation therapy patients.

Authors:  Hoda Sharifi; Gary C McDonald; Joon Kyu Lee; Munther I Ajlouni; Indrin J Chetty; Hualiang Zhong
Journal:  Quant Imaging Med Surg       Date:  2019-07

Review 2.  Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field.

Authors:  Huzaifa Piperdi; Daniella Portal; Shane S Neibart; Ning J Yue; Salma K Jabbour; Meral Reyhan
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.